AqueSys: Allergan : to Acquire Glaucoma Treatment Company AqueSys to Add Minimally Invasive Implantable Shunt to Eye Care Offering

(4-traders.com) 09.03.2015 | Investors - Acquisition Adds Global Rights to XEN45, a Minimally Invasive Best-In-Class Implantable Shunt for Glaucoma -- - XEN45 Approved in Global Markets; Late-Stage Development in the US -- - Bolsters All... - Acquisition Adds Global...http://www.4-traders.com/ALLERGAN-INC-11564/news/Allergan--to-Acquire-Glaucoma-Treatment-Company-AqueSys-to-Add-Minimally-Invasive-Implantable-Shunt-21017324/